

59. A pharmaceutical composition comprising the polypeptide of claim 36 and a pharmaceutically acceptable carrier.

60. A pharmaceutical composition comprising the polypeptide of claim 43 and a pharmaceutically acceptable carrier.

61. A pharmaceutical composition comprising the polypeptide of claim 50 and a pharmaceutically acceptable carrier. --

### **Remarks**

Claims 21-61 will be pending upon entry of this amendment.

The specification has been amended to correct typographical errors, to claim priority to a copending application, to insert sequence identifiers corresponding to disclosed sequences and to substitute the Sequence Listing with the Supplemental Sequence Listing submitted herewith.

Claim 21-61 have been added to more particularly point out and distinctly claim the subject matter Applicants regard as the invention. Support for the amendment of the claims is found throughout the specification as filed, as described below.

Support for the amendment of page 21, lines 24-29 of the specification to clarify the correct amino acid residues corresponding to the recited positions in Figure 1 and SEQ ID NO:2 is found in Figure 1 and Figure 4, which in combination, identify the correct residue at the recited position and that the amino acid sequences contained within the polypeptides defined by the recited positions have been predicted to bear an epitope of the NAF-1 protein of the invention.

Support for new claims 21-35 is found, for example, in the specification at page 5, lines 20-31; page 19, line 1 to page 20, line 17; and claim 17 as filed. Support for new claims 36-42 is found, for example, in the specification at page 4, lines 23-28; and page 20, line 30 to page 22, line 27. Support for new claims 43-49 is found for example, in the specification at

page 10, lines 16-33; page 13, lines 8-10; page 19, lines 24-26; and page 21, lines 15-18. Support for new claims 50-53 is found, for example, in the specification at page 10, lines 16-33; page 12, lines 25-35; and page 21, lines 15-18. Support for new claims 54-57 is found, for example, in the specification at page 7, lines 7-11; and page 18, lines 13-24. Support for new claims 58-61 is found, for example, in the specification at page 29, lines 31-37.


No new matter has been added.

### Conclusion

Applicants respectfully request that the amendments and remarks of the present Preliminary Amendment be entered and made of record in the present application. The application is believed to be in condition for allowance. Early notice to that effect is earnestly solicited. If, in the opinion of the examiner, a telephone conference would expedite prosecution, the undersigned can be reached at the telephone number indicated below. If a fee is required in connection with this paper, please charge Human Genome Sciences Inc., Deposit Account No. 08-3425 for the appropriate amount.

Respectfully submitted,

Date: October 13, 1998

  
Kenley K. Hoover (Reg. No. 40,302)  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 309-8504 (telephone)